Strs Ohio Grows Holdings in CRISPR Therapeutics AG $CRSP

Strs Ohio boosted its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP) by 335.6% during the 3rd quarter, HoldingsChannel reports. The firm owned 23,523 shares of the company’s stock after purchasing an additional 18,123 shares during the period. Strs Ohio’s holdings in CRISPR Therapeutics were worth $1,525,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also made changes to their positions in CRSP. Thompson Investment Management Inc. acquired a new stake in shares of CRISPR Therapeutics during the third quarter worth about $33,000. Bogart Wealth LLC raised its stake in CRISPR Therapeutics by 333.3% during the 3rd quarter. Bogart Wealth LLC now owns 650 shares of the company’s stock valued at $42,000 after acquiring an additional 500 shares during the last quarter. Atlantic Union Bankshares Corp acquired a new stake in CRISPR Therapeutics during the 2nd quarter worth approximately $33,000. Covestor Ltd purchased a new position in shares of CRISPR Therapeutics in the 3rd quarter valued at approximately $48,000. Finally, Strategic Wealth Investment Group LLC acquired a new position in shares of CRISPR Therapeutics in the second quarter valued at approximately $36,000. 69.20% of the stock is owned by hedge funds and other institutional investors.

CRISPR Therapeutics Trading Down 0.7%

Shares of CRISPR Therapeutics stock opened at $54.26 on Wednesday. The company has a 50-day moving average of $54.94 and a two-hundred day moving average of $58.35. CRISPR Therapeutics AG has a 12-month low of $30.04 and a 12-month high of $78.48. The stock has a market cap of $5.17 billion, a PE ratio of -9.71 and a beta of 1.70.

CRISPR Therapeutics (NASDAQ:CRSP) last released its quarterly earnings results on Monday, November 10th. The company reported ($1.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.32) by $0.15. CRISPR Therapeutics had a negative return on equity of 21.23% and a negative net margin of 1,273.70%.The business had revenue of $0.89 million for the quarter, compared to analysts’ expectations of $8.74 million. On average, sell-side analysts forecast that CRISPR Therapeutics AG will post -5.16 EPS for the current fiscal year.

Insider Buying and Selling at CRISPR Therapeutics

In other news, CEO Samarth Kulkarni sold 60,000 shares of CRISPR Therapeutics stock in a transaction on Thursday, January 22nd. The stock was sold at an average price of $60.23, for a total transaction of $3,613,800.00. Following the completion of the transaction, the chief executive officer owned 134,201 shares of the company’s stock, valued at $8,082,926.23. The trade was a 30.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 4.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

CRSP has been the subject of several recent research reports. Wells Fargo & Company set a $75.00 price target on CRISPR Therapeutics in a report on Monday, October 13th. Needham & Company LLC reissued a “buy” rating and set a $80.00 price target on shares of CRISPR Therapeutics in a report on Tuesday, December 23rd. Chardan Capital lowered their price objective on CRISPR Therapeutics from $82.00 to $74.00 and set a “buy” rating on the stock in a report on Wednesday, November 26th. Royal Bank Of Canada boosted their target price on CRISPR Therapeutics from $42.00 to $50.00 and gave the stock a “sector perform” rating in a research report on Tuesday, November 11th. Finally, Citigroup reissued a “buy” rating and issued a $77.00 price target (down from $87.00) on shares of CRISPR Therapeutics in a report on Tuesday, November 11th. Twelve equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $68.15.

CRISPR Therapeutics Profile

CRISPR Therapeutics AG is a biopharmaceutical company specializing in the development of gene-editing therapies based on the CRISPR/Cas9 platform. The company applies its proprietary technology to modify genes in human cells, aiming to create durable treatments for a range of serious diseases. Its research and development efforts focus on both ex vivo and in vivo applications, enabling targeted correction or disruption of disease-causing genes.

Among its lead programs is CTX001, an ex vivo edited cell therapy designed to treat sickle cell disease and transfusion-dependent β-thalassemia in collaboration with Vertex Pharmaceuticals.